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Disease Modiﬁcation and Other Trials in
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Have to Go Further
JANET E. POPE,1 DINESH KHANNA,2 SINDHU R. JOHNSON,3 AND PHIL CLEMENTS4
In this issue of Arthritis Care & Research, the View article
by Mendoza et al about clinical trial design in systemic
sclerosis (SSc; scleroderma) suggests that there cannot be a
universal design for clinical trials of disease modiﬁcation
in SSc because the disease has so many different presen-
tations (1). However, it is still important in any random-
ized controlled trial (RCT) to use proper statistics, includ-
ing sample size calculations, to be able to recruit subjects
(feasible), and ideally to have subjects enrolled that are
similar to SSc patients with comparable organ-based dis-
ease activity (generalizable). There will not be a single
design for every trial, but basic principles must be adhered
to. We have written this article as a counterview to the
views by Mendoza et al (1), but most of the opinions are in
agreement. The headings are ordered in a way that would
mimic the process of clinical trial design and conduct
(general principles, end points, and discussion of organ-
speciﬁc trials in SSc skin and lung). Examples from trials
of various rheumatic diseases have been provided to illus-
trate various aspects of trial design.
General principles of trial design
For a trial to be successful, a design with an adequate
sample size that is not overly optimistic and an analysis
plan developed before the trial starts will increase the
likelihood of success as measured by a statistically signif-
icant primary end point. Having an experienced statisti-
cian is recommended, as the analysis plan is critical for
trial development and the reporting of results. All random-
ized trials should be registered, and one web site for this is
http://register.clinicaltrials.gov.
Ethics of clinical trials. It is ethical to perform trials
when there is equipoise about a treatment (not being cer-
tain if it is effective or not, or if the risk/beneﬁt ratio is
favorable). Best available treatment (standard of care
[SOC]) can be offered in some studies. For instance, a new
drug can be compared to SOC in a blinded head-to-head
study or as an “add on” to SOC. These designs should be
double blind where possible. Some trials are performed
where SOC is denied and informed consent provides the
participants with the information that during the trial, a
speciﬁc SOC is not provided. This is the case in some
rheumatoid arthritis (RA) trials where, after failure of
methotrexate, a biologic agent is compared to a placebo
even though many approved treatments are available.
Withholding SOC may make recruitment very difﬁcult but
it is not unethical, provided patients are informed of treat-
ment options, understand some care is denied, and offer
consent. Participation in a trial is optional, not mandatory.
RCTs versus single-arm studies. Many diseases may
have heterogeneity, including systemic lupus erythemato-
sus, where there are various antibodies and differences in
organ activity and severity. For instance, lupus nephritis
has drugs demonstrated to be useful in randomized trials.
In SSc, disease modiﬁcation (or softening of the skin),
interstitial lung disease, and pulmonary arterial hyperten-
sion (PAH) are complications that have been studied in
well-conducted RCTs. SSc treatment of one organ such as
the skin should not be extrapolated to the treatment of
other organs.
The role of single-arm studies is to determine if there
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could be a reasonable expectation of beneﬁt with accept-
able risks in a future randomized trial. Most treatment in
SSc looks positive in open-label studies, but not in RCTs.
The main problems are the biases of open-label data, i.e.,
no comparison group, no blinding, and publication bias.
Reason for randomization. Fundamentally, randomiza-
tion distributes disease characteristics and potential con-
founders equally among the treatment groups. This is done
to decrease bias. Not all confounders are known, but ran-
domization should make the groups equal for both known
and unknown characteristics that could be associated with
the outcome of the trial. Stratiﬁcation at the time of ran-
domization can be used for some important characteristics
to fully ensure that the treatment groups are balanced with
respect to those variables. For instance, in a digital ulcer
study, there could be stratiﬁcation for the number of base-
line ulcers, such as one versus multiple ulcers (2 strata).
There will be equal allocation of subjects receiving study
treatments within each stratum, irrespective of the number
of patients who have multiple ulcers compared to those
with a single ulcer.
Parallel versus crossover design. Most RCTs use a par-
allel design (comparing one treatment to another or a pla-
cebo). Crossover trials are less common (where treatment
allocation is changed at least once at a time point, usually
in random treatment order). The advantage of a crossover
study is that fewer subjects are needed (because the patient
is compared to him/herself, which improves trial efﬁ-
ciency). However, the disadvantages include a carryover
effect (where the ﬁrst treatment has not worn off when the
second treatment begins and/or the patient is not back at a
baseline state) and an order effect (where the results are
affected by the order in which various treatments are re-
ceived). A true crossover design may be used in Raynaud’s
phenomenon (where the treatment effect starts and stops
quickly). This design is unlikely to occur in an SSc skin
trial, since it has been demonstrated that it takes many
months to see a clinical effect with most of the agents
studied to date.
Innovative trial designs. Perhaps combination treat-
ment in some SSc trials could be considered, such as in
PAH treatment. Combination therapy has been shown to
be successful in RA. Side effects of combining 2 treatments
may be higher, but potentially manageable when safety
rules such as dose reduction are written into the protocol.
Trial designs could include: A versus B (2-arm study), A
versus A  B (2-arm study), or A versus B versus A  B
(3-arm study). Strategies may compare active versus pla-
cebo or active versus active in the setting of adding to SOC
or comparing to SOC. In trials of psoriatic arthritis, an add
on of a tumor necrosis factor inhibitor to stable methotrex-
ate gives the same magnitude of beneﬁt as an add on to no
background methotrexate. A less common design is ran-
domized withdrawal, which has been used for biologic
agent studies in juvenile inﬂammatory arthritis. The prob-
lem is (and it is true in many instances in SSc) that if the
drug takes a long time to wash out or cause a rebound (and
the effect takes many months to be evident), then there
may be a Type II error.
Sample size calculation. It is imperative for the inves-
tigator to understand and account for the natural history of
the organ system he/she is interested in studying and to
identify and account for predictors of worsening during
the design phase of the study. This is true for any chronic
disease. In SSc trials, some patients get better, some get
worse, and some stay the same. Such trajectories have
been explored and demonstrated in a meta-analysis of
RCTs in diffuse cutaneous SSc (dcSSc) (2). Therefore,
when performing a sample size calculation, the variability
of the baseline characteristic of interest and the expected
change compared to the natural history of the disease
within the timeframe of the trial must be estimated. An
assumption needs to be made about how much the out-
come will change with treatment. Being overly optimistic
can lead to a negative trial (such as expecting 50% im-
provement in the active treatment group compared to no
response in the placebo group).
Trial duration: risk versus beneﬁt tradeoff. The study
needs to be long enough to determine a between-group
difference given the expectations of both natural history
and how treatment may alter this. If a drug is potentially
harmful, the trial should be as short as required to detect a
true difference so that patients are not exposed to unprov-
en/harmful treatments for longer than necessary. When
studying stem cell transplantation in SSc, the procedure
may rapidly improve skin (early beneﬁt) but increase mor-
tality after the transplant. Later, there may be sustained
improvement in major organs compared to patients not
receiving this intervention. The duration of observation
posttransplant must be sufﬁciently long to determine if the
beneﬁt is sustained and if there is an eventual survival
advantage over the comparator. Therefore, the Scleroder-
ma: Cyclophosphamide or Transplantation (SCOT) trial
was designed to be long enough to determine a future
survival beneﬁt and also to identify any recurrence of
disease.
Analysis of rare disease trial data. A disease is often
considered rare when the prevalence is less than 1 in 1,500
or less than 1 in 2,500 (as deﬁnitions vary between coun-
tries). Recruitment for trials may be less feasible in a rare
disease, particularly if there are strict inclusion and exclu-
sion criteria. The latter can also affect study generalizabil-
ity (3). There are analyses that may be helpful in rare
diseases with relatively small sample sizes. Johnson et al
reanalyzed the methotrexate trial by Pope et al using
Bayesian analysis and included imputation for missing
values. They found that methotrexate has a 94% probabil-
ity (16:1 odds) of a beneﬁcial effect on the modiﬁed Rod-
nan skin score (MRSS). There was an 88% probability (7:1
odds) of a beneﬁcial effect of methotrexate on physician
global assessment compared to placebo (4). These analyses
suggest that there are other methods of analysis that can
evaluate a difference in effects of the drug of interest
versus the comparison or placebo group that use the avail-
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able data, and are less susceptible to study power. How-
ever, Bayesian analyses can never make a negative trial
positive. It is a different way to analyze data: allowing
inferences to be made using the available data. Bayesian
methods are increasingly being used in observational stud-
ies (5,6) and clinical trials (7,8). Indeed, the US Food and
Drug Administration has guidelines for the use of Bayesian
methods in medical device clinical trials (9). There are
also more sophisticated analytical techniques for handling
missing or incomplete data other than the last observation
carried forward or intent-to-treat, which tends to harshly
penalize the test drug. Data that are randomly missing can
be analyzed using multiple imputation methods. Every
effort should be made to keep all patients returning for
their study visits, even if they have discontinued the study
medication.
Breaking the blind and adverse events (AEs). It may or
may not be possible to determine worsening SSc from AEs
related to the study medication. However, that is why
there is a comparison arm (to compare efﬁcacy but also
AEs). If a serious unexpected AE occurs, there may be
consideration of “breaking the code” (unblinding the sub-
ject’s treatment allocation). This may not be mandatory if
patients will be managed the same irrespective of what
study treatment they received.
Escape from treatment allocation (rescue), mandatory
withdrawal, and open-label extension. Mendoza et al
state that early escape or use of salvage arms in the study
design for patients with worsening lung and skin involve-
ment in SSc trials is strongly recommended (1). This de-
sign in RA trials has led to problems with the interpreta-
tion of results, where in some studies large numbers of
patients escape to an active treatment and randomization
after that time point is no longer in effect (10). There are
other ways to maintain treatment allocation. An escape
can be an “add-on therapy” to the study drug, which
maintains blinding and study treatment. Strict “treatment
failure” end points should be written into the protocol
where escape or adding other treatment is allowed (such
as 25% worsening of skin score or 15% worsening of
forced vital capacity [FVC] % predicted). Such patients
could be eligible to break the code, but only if that would
help in deciding future treatment. In the Scleroderma
Lung Study (SLS), for example, only 6 of the 158 entrants
were declared “treatment failures,” deﬁned as a decrease
in FVC % predicted by more than 15% of the predicted
value on 2 consecutive tests 30 days apart (11). Treatment
failures were taken off the study medication and were
eligible to have the drug code broken. Only 6 of the 158
patients requested a breaking of the drug code for medical
decision making. Once the code was broken, the patient
and the treating physician could decide on future therapy,
but the future therapy was not dictated by the study pro-
tocol. Treatment decisions were implemented outside the
treatment protocol. In the SLS, only 2 patients elected to
go on to cyclophosphamide (open therapy) after stopping
study medication. All of the patients were encouraged to
return for the 12-, 18-, and 24-month evaluations, even
though they might have discontinued the study medica-
tion earlier or started another therapy for lung disease.
Escape arms are a problem both scientiﬁcally and statisti-
cally, especially when there is no SOC for some aspects
of SSc. Therefore, salvage treatment does not salvage the
trial.
Some trials will have a mandatory dropout, but do not
offer the study drug. The subject returns to usual care.
Trials enrolling patients where SOC was not effective or
contraindicated (e.g., where a new agent is compared to
placebo) should not have a rescue arm, as there is no SOC
being denied. The ethics of this are clear. Perhaps a better
way of determining long-term safety and efﬁcacy is offer-
ing an open-label extension (providing the active study
drug once the trial is completed) or re-randomizing the
patients who are still blinded to receive treatment or pla-
cebo in a later time phase of a trial. Open-label extensions
may encourage recruitment but have potential risks, espe-
cially if there is no proven beneﬁt for the condition under
study (12).
Outcome measures/end points
Outcome Measures in Rheumatology has recommenda-
tions for validating outcome measurements, and this is an
ongoing resource for those designing trials in SSc (13).
Ideally, outcome measures should be valid, reliable, and
responsive to change. A number of outcome measures
have been formally evaluated in SSc (13,14).
Mortality is unlikely to be an end point in SSc trials
unless the patients included have a high anticipated mor-
tality or the trial is very long or extremely large. Mortality
data from the SCOT trial will soon be available comparing
stem cell transplant and cyclophosphamide in SSc pa-
tients who at entry had a risk of high mortality.
Objective measures. In open nonrandomized trials,
measures based on rater interpretation, such as the MRSS
or visual analog scales, are vulnerable to observation bias.
That is why a control group and double blinding are
needed. A single investigator must do all of the MRSS
evaluations on a given patient throughout a trial in order to
decrease error (eliminate interrater differences). A trained
experienced investigator is even better for reducing intra-
rater error.
Sample size calculations do not necessarily consider the
minimum important difference (MID) of the end point, but
secondary or exploratory outcomes may be based on the
MID (such as the proportion in each treatment arm that
obtains at least the MID for an outcome of interest). An
example of this is the change in a pulmonary function
parameter such as diffusing capacity or lung volume,
where there could be a statistically signiﬁcant between-
group difference, but the MID is not achieved as a mean
difference. However, there could be a higher proportion
that achieves the MID in the active treatment group.
A mean difference in an outcome measure may be below
the measurement error or precision of the test. For in-
stance, osteoporosis treatment may increase the bone min-
eral density above placebo by 3%, but the precision of the
dual x-ray absorptiometry machine is 3%. Measurement
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error should be equal between treatment groups, so the
clinical relevance of the results is not related to precision
of the measurement. The same would be true for FVC %
predicted in a scleroderma lung study.
Organ-speciﬁc trials: skin and lung as examples
Treatment to improve SSc skin. Two randomized pla-
cebo-controlled methotrexate trials yielded a positive and
a negative study (P value close to 0.05) (15,16). An overly
optimistic sample size calculation can lead to an under-
powered trial. The SLS, which was powered appropri-
ately, showed a signiﬁcant change in the MRSS at 12
months in the cyclophosphamide arm (11). Therefore, the
claim that “it can be accurately concluded that SSc skin
disease has no proven effective therapy” is not totally
accurate.
Other drugs have been studied in SSc to improve skin.
Mycophenolate mofetil has been tried in several case se-
ries, and in 1 study that provided matched controls ac-
quired by a chart audit, the changes in skin score may not
be different from historical controls (17). The use of his-
torical controls will not prove that treatment is effective,
but may inform the probability of a positive randomized
trial (e.g., yield preliminary data, particularly about
safety). As such, it is unlikely that imatinib will enter a
phase III trial in SSc because of its poor tolerability and
lack of superiority to historical controls (ref. 18 and
Distler O, et al: unpublished observations). Even so, well-
designed trials can help to determine if a treatment has an
advantage for AEs (19).
Use of a small dose of the study drug as a “placebo.”
Placebo-controlled trials should be performed wherever
possible, even in phase II trials. However, sometimes a
placebo cannot be made that looks, smells, and tastes
identical. The mini-dose of D-penicillamine used in low-
versus high-dose D-penicillamine in an early dcSSc trial
may have preserved blinding because the metallic taste
that can be seen with D-penicillamine was distributed
equally in both arms (20). The conclusion of the study
could be that a subclinical dose of the drug was equal to
usual dosing, or that the drug does not work. The latter
conclusion is widely accepted.
Consideration for lung trials: induction and mainte-
nance. Trials of interstitial lung disease in SSc could have
2 parts: induction and maintenance. Inclusion criteria and
end points must be deﬁned, such as “alveolitis.” In a lung
trial, there should be mandatory parameters such as FVC
% predicted and high-resolution chest computed tomog-
raphy evidence of pulmonary ﬁbrosis, ground glass, and
honeycombing.
Discussion
There have been many trials in rheumatic diseases with
several successful designs. Many end points in SSc trials
have been validated. Some successful treatments have
been demonstrated in RCTs in SSc. However, there is a
large unmet need in SSc because it has the worst prognosis
of the rheumatic diseases. Therefore, despite the rarity of
SSc, we have come a long way, but need to go further.
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